EXTENDED REPORT

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

Josef S Smolen,1 Désirée van der Heijde,2 Edward C Keystone,3 Ronald F van Vollenhoven,4 Mary B Goldring,5 Benoît Guérette,6 Mary A Cifaldi,6 Naijun Chen,6 Shufang Liu,6 Robert B M Landewé7

ABSTRACT

Objectives Tumour necrosis factor inhibition plus methotrexate is believed to inhibit radiographic progression independent of inflammation. This analysis assessed whether these protective effects are exerted on bone (joint erosion; JE) and/or cartilage (joint space narrowing; JSN), and what the independent effects of JE/JSN progression are on longer-term patient-reported outcomes.

Methods PREMIER was a 2-year, randomised, controlled trial of adalimumab plus methotrexate (ADA+MTX) versus the monotherapies. The impact of treatment on the relationships between time-averaged disease activity (TA-DAS28(CRP)) and changes in JE/JSN and associations of JE/JSN with the disability index of the health assessment questionnaire (HAQ-DI) at baseline and weeks 52 and 104 were assessed through non-parametric approaches of analysis of variance and quantile regression. JE/JSN association with employment status was evaluated at baseline and weeks 52 and 104 through logistic regression.

Results Increasing tertiles of TA-DAS28(CRP) were associated with JE and JSN progression in the monotherapy groups, a phenomenon largely absent in ADA+MTX-treated patients. Although JSN was not associated with HAQ-DI at baseline, it was at 52 and 104 weeks. In contrast, JE was not associated with HAQ-DI at any time point examined. Odds of being employed at baseline, 52 weeks and 104 weeks were significantly associated with lower JSN, but not JE, scores.

Conclusions ADA+MTX inhibited both JE and JSN progression independently of disease activity. JSN played a more prominent role in patient-reported outcomes than JE. Preventing the onset or worsening of JSN probably represents a critical aspect of effective disease management of early rheumatoid arthritis patients.

INTRODUCTION

In patients with rheumatoid arthritis (RA), both inflammation and joint damage can result in loss of physical function.1 2 Although the portion of physical disability that is associated with inflammation is generally reversible, the component associated with joint damage is thought to be largely permanent.3 Given the tight correlation between physical disability and loss of social and economic opportunities in patients with RA,4 treatment options capable of profoundly interfering with joint damage and inflammation would appear to be of greater individual and societal value.

The combination of a tumour necrosis factor (TNF) inhibitor and methotrexate reduces the risk of joint damage onset or progression and improves physical function more effectively than methotrexate alone.5–10 These benefits are thought to result partly from a more rapid and intense inhibition of inflammation with combination therapy than with methotrexate alone. However, patients treated with combination therapy tend to have minimal or no progression of joint damage regardless of inflammatory activity; whereas the level of joint damage tends to reflect the extent of inflammation in methotrexate-treated patients,11–15 suggesting that combination therapy may inhibit joint damage through mechanisms that are independent of inflammatory activity. Alternatively, the TNF cytokine may cause joint damage only after it exceeds some threshold that is greater than that required to cause inflammation.16

Joint damage results from the destruction of bone and cartilage, which can be visualised through radiography as joint erosion (JE) and joint space narrowing (JSN), respectively. While JSN is a surrogate marker for loss of cartilage, it may also reflect damage to other (soft) tissues causing joint dislocation, a phenomenon that is less prevalent among patients with early RA. Although JE historically has been perceived to be the most critical indicator of permanent disability in RA patients, recent data suggest that, early in the disease process, JSN may be the more important predictor of irreversible physical disability, as measured by the residual score on the disability index of the health assessment questionnaire (HAQ-DI) in patients whose disease is in remission.17 18

In the present analysis, we evaluated the joint-protective effects of three different therapies, the combination of adalimumab plus methotrexate...
(ADA+MTX), adalimumab monotherapy and methotrexate monotherapy, on JE and JSN as a function of inflammatory activity, using data from a randomised, controlled trial of methotrexate-naive patients with early RA. The relationships between JE or JSN and physical function and employment status were also evaluated.

METHODS

Study design

Data from patients enrolled in the PREMIER trial were used for all analyses. PREMIER was a 2-year, active-controlled, double-blind study of methotrexate-naive patients with early, progressive RA, in which patients were randomly assigned to the following treatment groups: combination treatment with subcutaneous adalimumab (40 mg every other week) and oral methotrexate (titrated to 20 mg/week by week 8, as tolerated), adalimumab monotherapy, or methotrexate monotherapy. Employment outcomes were assessed in a large subset of patients who participated in the DE052 companion study. All patients provided written, informed consent, and the study protocols and informed consent forms were approved by the local institutional review boards or independent ethics committees at participating sites. The studies were conducted in accordance with the principles of the Declaration of Helsinki and good clinical practice.

Patient characteristics

Adults aged 18 years and older with an RA diagnosis, as defined by the 1987-revised American College of Rheumatology criteria, were eligible for enrolment. Patients must have satisfied the following inclusion criteria: disease duration less than 3 years, eight or more swollen joints (out of 66 assessed), 10 or more tender joints (out of 68 assessed), either an erythrocyte sedimentation rate greater than 28 mm/h or C-reactive protein concentration of 1.5 mg/dl or greater and either rheumatoid factor positivity or at least one JE. Patients were excluded if they had received previous treatment with methotrexate, cyclophosphamide, ciclosporin, azathioprine, more than two disease-modifying antirheumatic drugs, or prednisone equivalent greater than 10 mg/day within 30 days of screening.

Clinical, radiographic, functional and employment assessments

The 28-joint disease activity score with CRP (DAS28(CRP), range 0–10; hereafter referred to as DAS28) was used to monitor disease activity. DAS28 was calculated at baseline and regular intervals to week 104. A time-averaged DAS28 (TA-DAS28) was calculated in order to control for intergroup differences in speed of responses and longitudinal fluctuations in inflammation. To obtain TA-DAS28, areas under the curve were determined for all time intervals of available DAS28 values from baseline to 52 or 104 weeks for individual patients. Values were summed and divided by the total time interval. The distribution of TA-DAS28 values for all patients was then divided into tertiles at each assessment point. Radiographs of the hands and feet were taken at baseline and weeks 52 and 104. Two readers, blinded to patient and sequence, scored radiographs individually for bone erosion (JE, range 0–250) and JSN (range 0–168) using a modified form of the Sharp scoring method (modified total Sharp score; mTSS). Physical function was evaluated using the HAQ-DI at baseline, week 52 and week 104. Employment status (either employed or unemployed) was collected at baseline and at weeks 52 and 104. At each time point, a patient was asked if there was a change in employment status from the previous visit.

Statistical analysis

Descriptive analyses of changes in disease activity included observed data from patients who completed 52 or 104 weeks of treatment, had one or more post-baseline DAS28 and underwent radiography at baseline and weeks 52 or 104. Analyses of the relationships between HAQ-DI and JE or JSN included observed data from patients with available HAQ-DI, radiographic data and DAS28 at baseline, week 52, or week 104. Analysis of the relationships between employment status and JE or JSN included observed data from patients with available employment status, radiographic data and HAQ-DI at baseline, week 52, or week 104.

Overall mean changes from baseline in DAS28 were calculated at weeks 52 and 104 for the analysis population by treatment group. At weeks 52 and 104, the associations between TA-DAS28 tertiles and changes from baseline in JE and JSN were compared for patients who received ADA+MTX combination therapy, adalimumab monotherapy, or methotrexate monotherapy between and within treatment groups using an analysis of variance on the van der Waerden normal scores.

The relationships between HAQ-DI and JE or JSN at baseline, week 52 and week 104 were evaluated using quantile (non-parametric) regression models. Each model evaluated the relationships between HAQ-DI and either concurrent JE or JSN as independent variables after covariate adjustment for concurrent DAS28 and baseline disease duration, age and sex.

The relationships between employment status and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic regression models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex. The relationship between baseline JE or JSN and baseline employment status was further evaluated by calculating tertiles of JE or JSN and determining the percentages of patients in each tertile who were employed at baseline; differences across JE or JSN tertiles were evaluated through $\chi^2$.

RESULTS

Relationship between disease activity and changes in joint damage

Of the 799 patients originally randomly assigned in PREMIER, 638 (including 229 of 268, 205 of 274 and 204 of 257 patients randomly assigned to receive ADA+MTX, adalimumab and methotrexate, respectively) had one or more post-baseline DAS28 and underwent radiography at baseline and week 52 and/or week 104. No significant differences between treatment groups were detected in the baseline demographics and disease characteristics for the patients included in this analysis (table 1). As would be expected for a patient population with short disease duration, baseline radiographic scores were generally low.

Following 52 and 104 weeks of treatment, patients receiving ADA+MTX combination therapy had greater mean reductions from baseline in DAS28 (−3.6 and −3.8, respectively) than patients receiving adalimumab monotherapy (−2.8 and −3.1, respectively) or methotrexate monotherapy (−2.8 and −3.1, respectively). This pattern of treatment responses was evident at week 2 and maintained throughout the 104-week study (data not shown).

The between-group differences in DAS28 response resulted in different distributions of patients across the TA-DAS28 tertiles between the combination and monotherapy treatment groups: approximately half of the patients receiving combination treatment with ADA+MTX had a TA-DAS28 in the lowest tertile at baseline, compared with 24% of patients receiving adalimumab monotherapy and 26% of patients receiving methotrexate monotherapy. Similar differences were observed at weeks 52 and 104.
therapy were in the lowest TA-DAS28 tertile, while patients receiving either adalimumab or methotrexate monotherapy were clustered in the higher TA-DAS28 tertiles (see n and percentage in each treatment group over time presented in figures 1 and 2).

The relationships between TA-DAS28 tertiles and changes in JE or JSN were different between treatment groups. In the ADA+MTX group, the relationship between TA-DAS28 and changes in JE and JSN was more pronounced for the middle DAS28 tertiles of JE (p<0.01). Indeed, there was less overall progression of employed patients generally decreased with increasing baseline values of JE or JSN, the percentages of employed patients generally decreased with increasing baseline values of JE or JSN, the percentages of employed patients generally decreased with increasing baseline values of JE or JSN, and JSN were different between treatment groups. In the ADA+MTX group, the relationship between TA-DAS28 tertiles and changes in JE and JSN was more apparent for JSN (p=0.02 vs p<0.001 for the overall differences among JE and JSN tertiles, respectively; figures 3B,C).

### Relationship between JE or JSN and employment

Of the 664 patients originally enrolled in the study of employment outcomes, 649 (98%) had available employment status at baseline. Being younger, male and having less disability were associated with being employed at baseline and weeks 52 and 104; shorter disease duration was associated with being employed at baseline but not at the later time points (data not shown). While the presence of JE did not convey a significant impact on employment status at any time point evaluated, small, but statistically significant, associations were found between JSN scores and being employed at baseline (OR 0.97, p=0.02) and weeks 52 (OR 0.97, p=0.007) and 104 (OR 0.98, p=0.04) (figure 3A). When baseline employment status was assessed solely by baseline levels of JE or JSN, the percentages of employed patients generally decreased with increasing baseline values of JE or JSN, although the relationship was more apparent for JSN (p=0.02 vs p<0.001 for the overall differences among JE and JSN tertiles, respectively; figures 3B,C).

### Relationship between JE or JSN and physical function

A total of 765 patients from PREMIER had available HAQ-DI, radiographic data and DAS28 at baseline, week 52, or week 104. In quantile regression models, age, female sex and disease activity (DAS28) generally were all positively associated with physical function: while JE scores were not associated with HAQ-DI at any of the time points examined, JSN scores were positively associated with HAQ-DI scores at both 52 and 104 weeks (table 3). The relationship between JSN and HAQ-DI was less evident at baseline, presumably due to either the dominating effect of disease activity or the level of baseline damage in this population not meeting the threshold required to observe an effect on physical function. Treatment effect, baseline steroid use and osteoarthritis status did not appear to impact HAQ-DI scores additionally (data not shown).

### Table 1 Baseline demographics and disease characteristics of patients included in analyses of PREMIER*

| Baseline characteristic | ADA+MTX (N=229) | ADA (N=205) | MTX (N=204) |
|-------------------------|-----------------|------------|-------------|
| Age (years)             | 51.9±14.0       | 51.9±12.9  | 52.8±13.3   |
| Female, n (%)           | 162 (70.7)      | 156 (76.1) | 153 (75.0)  |
| Race (white), n (%)     | 218 (95.2)      | 193 (94.1) | 191 (93.6)  |
| Disease duration (years)| 0.7±0.8         | 0.7±0.8    | 0.8±0.9     |
| Rheumatoid factor positive, n (%) | 187 (83.9) | 179 (88.6) | 172 (86.0) |
| Previous DMDAR use, n (%) | 72 (31.4)     | 69 (33.7)  | 61 (29.9)   |
| Baseline corticosteroid use, n (%) | 82 (35.8) | 74 (36.1)  | 68 (33.3)  |
| SJC (66)                | 23.1±11.5       | 21.7±10.4  | 22.2±12.0   |
| TJC (68)                | 30.5±14.4       | 32.5±13.7  | 32.0±14.2   |
| DAS28(CRP)              | 6.3±0.9         | 6.3±0.9    | 6.3±0.9     |
| HAQ-DI                  | 1.5±0.6         | 1.6±0.6    | 1.5±0.7     |
| CRP (mg/dl)             | 4.0±4.3         | 3.8±3.6    | 4.0±4.1     |
| mTSS                    | 18.7±20.6       | 18.9±18.8  | 22.2±22.5   |
| JE                      | 11.4±12.8       | 11.5±11.4  | 13.8±13.7   |
| JSN                     | 7.3±9.4         | 7.4±8.8    | 8.4±10.8    |
| Employed, n (%)††       | 109 (60.2)      | 88 (52.1)  | 99 (58.2)   |

All values are mean±SD, unless otherwise indicated.

*Includes data from patients who completed 52 and/or 104 weeks of treatment, had at least one post-baseline DAS28(CRP), and underwent radiography at baseline and week 52 and/or 104.

1A total of 181, 169 and 170 patients from the ADA+MTX, ADA, and MTX groups, respectively, had employment data at baseline.

ADA, adalimumab; CRP, C-reactive protein; DMDAR, disease-modifying antirheumatic drug; DAS28, 28-joint disease activity score; HAQ-DI, disability index of the health assessment questionnaire; JE, joint erosion; JSN, joint space narrowing; MTX, methotrexate; mTSS, modified total Sharp score; SJC, swollen joint count; TJC, tender joint count.

---

**Figure 1** Changes in joint erosion (JE) by time-averaged 28-joint disease activity score (TA-DAS28(C-reactive protein (CRP))) tertiles. Changes in JE are shown over 52 weeks (A) and 104 weeks (B) by tertiles of TA-DAS28(CRP). *p<0.05 for treatment group difference compared with methotrexate (MTX) monotherapy; **p<0.01; ***p<0.001. Figures show the median (solid line), mean (dotted line) and IQR (bars). ADA, adalimumab.
Effect Baseline Coefficient (95% CI) p Value 52 Weeks Coefficient (95% CI) p Value 104 Weeks Coefficient (95% CI) p Value
Model including JE
N=785 N=581 N=511
Age 0.009 (0.006 to 0.013) <0.001 0.004 (0.001 to 0.007) 0.01 0.005 (0.002 to 0.008) 0.002
Female 0.272 (0.176 to 0.368) 0.01 0.084 (0.013 to 0.166) 0.04 0.063 (0.017 to 0.143) 0.12
C-reactive protein (CRP) 0.371 (0.317 to 0.426) 0.001 0.296 (0.256 to 0.336) <0.001 0.302 (0.263 to 0.341) <0.001
JE −0.001 (−0.005 to 0.004) 0.79 −0.000 (−0.004 to 0.004) 0.96 −0.001 (−0.003 to 0.002) 0.63
Duration of RA (years) −0.031 (−0.075 to 0.013) 0.17 0.003 (−0.045 to 0.050) 0.92 0.033 (−0.014 to 0.079) 0.17
Model including JSN
N=785 N=581 N=511
Age 0.009 (0.005 to 0.012) <0.001 0.004 (0.001 to 0.007) 0.01 0.004 (0.001 to 0.007) 0.01
Female 0.252 (0.155 to 0.341) <0.001 0.108 (0.032 to 0.185) 0.006 0.051 (−0.026 to 0.129) 0.17
C-reactive protein (CRP) 0.369 (0.312 to 0.425) <0.001 0.284 (0.241 to 0.326) <0.001 0.281 (0.240 to 0.322) <0.001
JSN 0.002 (−0.003 to 0.008) 0.33 0.006 (0.001 to 0.011) 0.03 0.005 (0.000 to 0.011) 0.046
Duration of RA (years) −0.040 (−0.088 to 0.009) 0.11 −0.006 (−0.053 to 0.042) 0.81 0.008 (−0.038 to 0.055) 0.73

CRP, C-reactive protein; DAS28, 28-joint disease activity score; HAQ-DI, disability index of the health assessment questionnaire; JE, joint erosion; JSN, joint space narrowing; RA, rheumatoid arthritis.

DISCUSSION

The hallmarks of RA—inflammation, damage to bone and cartilage, and physical disability—are thought to be interrelated processes that often progress rapidly following disease onset. Treatment with the combination of a TNF inhibitor and methotrexate often limits, or even prevents, joint damage in patients who may lack an otherwise measurable clinical response.11–15 Our results further refine the understanding of this clinical and functional benefit by demonstrating that ADA+MTX protects against JE and JSN onset or worsening; both of these benefits are also largely independent of the therapeutic effect on inflammatory activity.

Earlier analyses have not evaluated the individual effects of anti-TNF plus methotrexate on JE and JSN progression in response to disease activity.11–15 These findings reveal that both JE and JSN increase consistently with increasing disease activity in patients treated with methotrexate monotherapy. Interestingly, a similar trend in JE and JSN increase in relation to disease activity is seen with adalimumab monotherapy. However, a recent analysis suggests that adalimumab provides better joint protection than methotrexate in individual joints with pre-existing damage, irrespective of the presence of synovitis.29 Importantly, ADA+MTX reduces the progression of both JE and JSN in a manner that is independent of disease activity. Interestingly, the relationship between disease activity and JSN progression appeared less prevalent than with JE progression, suggesting that ADA+MTX may have even stronger inhibitory effects on JSN progression than on JE progression.
despite persistent inflammation. Alternatively, the threshold of TNF required to elicit JSN may be higher than that required to cause erosive damage. This novel finding on the abrogation of effects of disease activity on JSN by combination therapy with ADA+MTX appears to be of particular importance in light of recent observations that JSN may affect physical function more profoundly than bony joint damage. Indeed, the present analysis expands these findings by demonstrating that in early RA patients progression of JSN, but not JE, is not only significantly associated with loss of physical function, but that JSN progression also has an adverse effect on employment status not seen with JE progression, even at this early stage of disease.

A positive association between physical function and joint damage has been documented in advanced RA. Less profound than bony joint damage, indeed, the present analysis expands these findings by demonstrating that in early RA patients progression of JSN, but not JE, is not only significantly associated with loss of physical function, but that JSN progression also has an adverse effect on employment status not seen with JE progression, even at this early stage of disease.

Figure 3  Relationship between radiographic measures and employment status. (A) Logistic regression analysis of the relationship between joint erosion (JE) or joint space narrowing (JSN) and employment status at baseline, 52 weeks and 104 weeks. Percentages of patients who were employed at baseline within each baseline JE (A) or JSN (B) tertile.

Although previous results are suggestive of an interconnected association between joint damage, physical function and employment status, the relative contribution of JE and JSN progression to employment status has not yet been evaluated. Our data indicate that progression of JSN plays a more prominent role than JE in determining employment status. Patients with RA frequently lose their jobs early in the course of the disease, with 20–30% experiencing permanent work disability during the first 2–3 years after diagnosis. These data indicate that early control of JSN progression is important not only to protect patients’ physical functioning but to help them maintain the lifestyle they had before RA diagnosis. A similar association with reduced physical function and job impairment is observed in patients with osteoarthritis; however, there is no evidence that existing osteoarthritis independently impacted JE or JSN progression or HAQ-DI scores in this database.

Several limitations must temper the interpretation of the results of this study. Although the radiographic endpoints used are widely reported and validated, they remain surrogate measures that rely on visual representation and interpretation of joint damage and can be subject to error and bias. Furthermore, as JSN is not a direct measure of cartilage damage, surrounding tissues may also be damaged, and the JSN measurement technique cannot determine the relative contributions of these tissues. Still, such contribution is less likely at this early stage of disease. The joints analysed for JE and JSN also often limitations. Larger joints, such as joints of the knee, may impact physical function and employability to a greater extent than the joints of the hands, wrist and feet that are scored for JE and JSN, and an examination into grip strength in relation to these patient-reported outcomes may have produced greater correlations. However, it is important to note that this study included patients with an average disease duration of less than
1 year; therefore, finding a statistically significant association between these variables at this early stage of RA portends a high risk of a much larger consequence if damage were allowed to accrue over longer periods. Differences in patient discontinuations over time represent a further limitation. Still, the observed differences between treatment groups may have been more pronounced had rates of discontinuation been comparable across treatment groups. Finally, the post-hoc nature of these analyses should be considered to be hypothesis generating and require confirmation in other databases of patients with early RA.

CONCLUSIONS
In this population with early, progressive RA, JSN progression was associated with impairment in physical function and work status throughout 2 years of treatment, but JE progression was not. Because of the clinical implications of JSN progression for disability and work impairment, protection from the onset or worsening of JSN should be an important factor when choosing between therapeutic modalities. Combination therapy with ADA+MTX suppresses JE and JSN progression and does so in a manner independent of clinical disease activity.

Acknowledgements Medical writing assistance in the development and revision of this manuscript was provided by Benjamin Wolfe, PhD, and Troy Scott, DVM, of Abbott, and Ellen Stolzfus, PhD, and Robin Stromberg, PhD, of JK Associates, Inc. This support was funded by Abbott.

Contributors All authors participated in interpretation of the data, critically revised the manuscript and approved the final version.

Funding Abbott sponsored the study (NCT00195663) and contributed to the study design.

Competing interests JSS has received consulting fees or other remuneration from Abbott, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz and UCB, research grants from Abbott, BMS, Pfizer (Wyeth), MSD (Schering-Plough), Roche and UCB, and has served on speaker’s bureaux on behalf of Abbott, BMS, Centocor-Janssen, Pfizer (Wyeth), MSD (Schering-Plough), Roche, Sandoz and UCB. DMvDH has received consulting fees or other remuneration from Abbott, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB and Wyeth. ECK has received consulting fees or other remuneration from and, served on advisory boards on behalf of, Abbott, AstraZeneca, Biostem, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from Abbott, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has served on speaker’s bureaux on behalf of, Abbott, AstraZeneca, Biostem, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB, has received research grants from Abbott, Amgen, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has served on speaker’s bureaux on behalf of, Abbott, AstraZeneca, Biostem, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB. DMvDH has received consulting fees or other remuneration from Abbott, AstraZeneca, BMS, Centocor, Genzyme, Merck, Novartis, Pfizer, Roche and UCB, and has served on speaker’s bureaux on behalf of, Abbott, AstraZeneca, Biostem, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB. ECK has received consulting fees or other remuneration from and, served on advisory boards on behalf of, Abbott, AstraZeneca, Biostem, BMS, Centocor, Genentech, Merck, Nycomed, Pfizer, Roche and UCB.

Ethics approval The study protocols were approved by the local institutional review boards or independent ethics committees at participating sites.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
1. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.
2. Drosaars-Bakker KW, de Buck M, van Zeelen D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854–60.
3. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92.
4. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol 2010;28:S32–40.
5. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. New Engl J Med 2000;343:1584–92.
6. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.
7. Klareskog L, van der Heije D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.
8. St Clair EW, van der Heije DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
9. Breedveld FC, Steiman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had no previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
10. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (DOMET): a randomised, double-blind, parallel trial trial. Lancet 2006;368:375–82.
11. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020–30.
12. Landewé R, van der Heije D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119–25.
13. Smolen JS, van der Heijke DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702–10.
14. Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2008;35:1429–41.
15. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients awaiting different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:623–7.
16. Smolen JS, Aletaha D, Grisar J, et al. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008;10:208.
17. Aletaha D, Funovits J, Smolen JS. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis 2011;70:733–9.
18. Landewé R, van der Heijde D. Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions? Ann Rheum Dis 2011;70:717–18.
19. van Vollenhoven RE, Ciftiad MA, Ray S, et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res 2010;62:226–34.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
21. Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
22. Plant MJ, Saklatvala J, Borg AA, et al. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994;21:1808–13.
23. Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1987;14:706–20.
24. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326–35.
25. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:769–83.

Ann Rheum Dis © 2012 by the British Society for Rheumatology. Published by BMJ Publishing Group Ltd. All rights reserved. doi:10.1136/annrheumdis-2012-201620
26. Conover W. *Practical nonparametric statistics*, 3rd edn. Hoboken (NJ): John Wiley & Sons, 1999.

27. Odegard S, Landewé R, van der Heijde D, et al. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. *Arthritis Rheum* 2006;54:68–75.

28. van der Heijde D, Landewé R, van Vollenhoven R, et al. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. *Ann Rheum Dis* 2008;67:1267–70.

29. Landewé R, Smolen J, Keystone E, et al. Existing joint erosions increase the risk of joint space narrowing independently of the presence of clinical synovitis in patients with early rheumatoid arthritis (abstract). *Ann Rheum Dis* 2011;70(Suppl. 3):412.

30. van der Heijde D, Landewé R, Guérette B, et al. Joint space narrowing has a stronger impact on physical function than joint erosion: results from 8-year longitudinal analyses (abstract). *Arthritis Rheum* 2010;62(Suppl.):S466–7.

31. van Vollenhoven R, Cifaldi M, Chen N, et al. Radiographic progression predicts physical function in early rheumatoid arthritis: results from the PREMIER study (abstract). *Ann Rheum Dis* 2009;68(Suppl. 3):S488.

32. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. *J Rheumatol* 2004;31:849–55.

33. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. *Drugs* 2010;70:121–45.

34. Sokka T. Work disability in early rheumatoid arthritis. *Clin Exp Rheumatol* 2003;21:S71–8.

35. Salaffi F, Carotti M, Stancati A, et al. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. *Aging Clin Exp Res* 2005;17:255–63.
Correction

Smolen JS, van der Heijde DM, Keystone EC, et al. *Ann Rheum Dis* 2013;72:1156–62. The third sentence of figure 3 legend mistakenly refers back to panels (A) and (B), whereas it should refer to panels (B) and (C). The correct sentence is: Percentages of patients who were employed at baseline within each baseline JE (B) or JSN (C) tertile.

*Ann Rheum Dis* 2013;72:1432. doi:10.1136/annrheumdis-2012-201620corr1